Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, August 26 '25)

Image
By G.M.

 


    Antiviral Res

  1. GUAN S, Wang Q, Nie J, Yao X, et al
    Optimization of the monoclonal antibody 3E1 through W32I mutation enhances antiviral efficacy against influenza virus subtypes H1N1 and H3N2.
    Antiviral Res. 2025;242:106260.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  2. GABELMANN A, Biesel A, Loretz B, Lehr CM, et al
    Exploring the future of mRNA delivery: Beyond lipid nanoparticles.
    Biochem Biophys Res Commun. 2025;778:152347.
    PubMed         Abstract available


    Biochemistry

  3. SUBRAMANIAM S, Saville JW, Feng F, Freiburger L, et al
    Therapeutic Antibodies for Infectious Diseases: Recent Past, Present, and Future.
    Biochemistry. 2025;64:3487-3494.
    PubMed         Abstract available


    Epidemiol Infect

  4. CHOI H, Hwang M, Coppin JD, Chatterjee P, et al
    Penetration of SARS-CoV-2 Alpha, Delta, and Omicron variants in the United States.
    Epidemiol Infect. 2025;153:e92.
    PubMed         Abstract available

  5. WU S, Feng Y, Cheng H, Huang H, et al
    Personalized risk score prediction and testing policy adaptations of a COVID-19 population-based contact tracing network.
    Epidemiol Infect. 2025;153:e90.
    PubMed         Abstract available

  6. DO DA, Duy-Nguyen VM, Nguyen TH, Le DT, et al
    Antibiotic resistance among ICU patients during the COVID-19 pandemic and its associated factors: a retrospective study using electronic medical records in two Vietnamese hospitals.
    Epidemiol Infect. 2025;153:e93.
    PubMed         Abstract available


    J Clin Microbiol

  7. BASSIT L, Damhorst GL, Bowers HB, Sabino C, et al
    Toward diagnostic preparedness: detection of highly pathogenic avian influenza A(H5N1) in contrived nasal swab specimens using rapid antigen and point-of-care molecular tests.
    J Clin Microbiol. 2025 Aug 19:e0054825. doi: 10.1128/jcm.00548.
    PubMed         Abstract available


    J Infect

  8. ZHANG S, Liang H, Xu J, Chen B, et al
    Spatial-temporal Dynamics and Virus Interference of Respiratory Viruses: Insights from Multi-Pathogen Surveillance in China.
    J Infect. 2025 Jul 22:106556. doi: 10.1016/j.jinf.2025.106556.
    PubMed         Abstract available

  9. MALLINSON PA, Dasi T, Banjara SK, Lieber J, et al
    Impact of distribution of facemasks on community incidence and outcomes of COVID-19: A cluster randomised trial in India.
    J Infect. 2025 Jul 23:106557. doi: 10.1016/j.jinf.2025.106557.
    PubMed         Abstract available

  10. MCGEOCH LJ, Foulkes S, Whitaker H, Munro K, et al
    Effectiveness of influenza vaccination against infection in UK healthcare workers during winter 2023-24: The SIREN cohort study.
    J Infect. 2025;91:106585.
    PubMed         Abstract available

  11. SONG X, Hou X, Li Y, Zhang R, et al
    Prevalence and Transmission of Influenza A (H6) Viruses Pose a Potential Threat to Public Health.
    J Infect. 2025 Aug 19:106594. doi: 10.1016/j.jinf.2025.106594.
    PubMed        


    J Infect Dis

  12. BAUM HE, Santopaolo M, Francis O, Milodowski EJ, et al
    Hybrid B- and T-Cell Immunity Associates With Protection Against Breakthrough Infection After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Avon Longitudinal Study of Parents and Children (ALSPAC) Participants.
    J Infect Dis. 2025 May 20:jiaf246. doi: 10.1093.
    PubMed         Abstract available

  13. CHEN H, Huang X, Wang C, Cowling BJ, et al
    Estimating the waning effectiveness of COVID-19 vaccines from population-level surveillance data in Hong Kong.
    J Infect Dis. 2025 Apr 18:jiaf207. doi: 10.1093.
    PubMed         Abstract available

  14. WESTERHOF I, Sikkema R, Rozhnova G, van Beek J, et al
    The Effect of Preexisting Coronavirus Antibodies on Severe Acute Respiratory Syndrome Coronavirus 2 Infection Outcomes in Exposed Household Members.
    J Infect Dis. 2025;232:e318-e326.
    PubMed         Abstract available

  15. PASANEN A, Karjalainen MK, Korppi M, Hallman M, et al
    Genetic Susceptibility to Acute Viral Bronchiolitis.
    J Infect Dis. 2025;232:e193-e202.
    PubMed         Abstract available


    J Virol

  16. ROBINSON-MCCARTHY LR, Simmons HC, Graber AL, Marble CN, et al
    Dairy cattle herds mount a characteristic antibody response to highly pathogenic H5N1 avian influenza viruses.
    J Virol. 2025 Aug 25:e0062125. doi: 10.1128/jvi.00621.
    PubMed         Abstract available

  17. SAEIDI S, Wan H, Kang H, Gao J, et al
    N-linked glycans on the stalk of influenza virus neuraminidase promote functional tetramer formation by compensating for local hydrophobicity.
    J Virol. 2025 Aug 18:e0087925. doi: 10.1128/jvi.00879.
    PubMed         Abstract available


    J Virol Methods

  18. MAROTTA MG, Neto MM, Daly J, Maina M, et al
    Development and optimisation of Influenza C and Influenza D pseudotyped viruses.
    J Virol Methods. 2025 Aug 23:115243. doi: 10.1016/j.jviromet.2025.115243.
    PubMed         Abstract available


    Lancet

  19. NEPOGODIEV D, Picciochi M, Ademuyiwa A, Adisa A, et al
    Surgical health policy 2025-35: strengthening essential services for tomorrow's needs.
    Lancet. 2025 Jul 14:S0140-6736(25)00985-7. doi: 10.1016/S0140-6736(25)00985.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  20. BOUNDY EO, Fast H, Jatlaoui TC, Razzaghi H, et al
    Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination - United States, October 2023-March 2024.
    MMWR Morb Mortal Wkly Rep. 2025;74:484-489.
    PubMed         Abstract available


    N Engl J Med

  21. MCINTYRE L, Fergusson D, McArdle T, English S, et al
    A Crossover Trial of Hospital-Wide Lactated Ringer's Solution versus Normal Saline.
    N Engl J Med. 2025 Jun 12. doi: 10.1056/NEJMoa2416761.
    PubMed         Abstract available


    PLoS Comput Biol

  22. STEWART L, Evans S, Brevini T, Sampaziotis F, et al
    Modelling the potential use of pre-exposure prophylaxis to reduce nosocomial SARS-CoV-2 transmission.
    PLoS Comput Biol. 2025;21:e1013361.
    PubMed         Abstract available


    PLoS One

  23. ROCHA C, Arora P, Zhang L, Sidarovich A, et al
    Amino acid residues 655 and 969 in the spike protein of Omicron subvariant BA.1 control use of TMPRSS2 versus Cathepsin L dependent entry pathways and cell tropism.
    PLoS One. 2025;20:e0328879.
    PubMed         Abstract available

  24. VILLENEUVE PJ, Cottagiri SA, Jiang Y, De Groh M, et al
    Residential greenness and reduced depression during COVID-19: Longitudinal evidence from the Canadian Longitudinal Study on Aging.
    PLoS One. 2025;20:e0329141.
    PubMed         Abstract available

  25. DANOK L, Burke J, MacDonald T, Cheema S, et al
    Identifying models of care to support residents in long-term care homes (LTCHs) both during and beyond COVID-19.
    PLoS One. 2025;20:e0329255.
    PubMed         Abstract available

  26. OTI O, Foley S, Pitt I
    Students' attitudes and experiences toward mental health support services in Ireland: A qualitative study.
    PLoS One. 2025;20:e0329905.
    PubMed         Abstract available

  27. CREEDON S, Trace A
    From protection of sacrificial self to critical turning points and growth: Redeployed nurses' experiences on the frontline during the COVID-19 pandemic.
    PLoS One. 2025;20:e0314830.
    PubMed         Abstract available

  28. MARTIN-ESCOLANO J, Ruiz-Molina A, Rodriguez-Urbistondo C, Infante-Dominguez C, et al
    Factors associated with SARS-CoV-2 RNAemia development at COVID-19 diagnosis.
    PLoS One. 2025;20:e0330495.
    PubMed         Abstract available

  29. SULTANA GNN, Hasan MZ, Das A, Sarker R, et al
    Evaluating the MT-CYB and MT-ATP6 variations in COVID-19 patients: A case-control study.
    PLoS One. 2025;20:e0329866.
    PubMed         Abstract available

  30. MULFINGER N, Jarczok MN, Muller A, Genrich-Hasken M, et al
    Effectiveness of a multilevel intervention to improve mental health of hospital workers: The SEEGEN multicenter cluster randomized controlled trial.
    PLoS One. 2025;20:e0330490.
    PubMed         Abstract available

  31. LEE M
    A cross-sectional study of COVID-19 testing and disclosure hesitancy: The role of responsibility attribution in South Korea.
    PLoS One. 2025;20:e0330737.
    PubMed         Abstract available

  32. REESE EM, Lines N, Thacker EL, Barnes MD, et al
    Association of COVID-19 stimulus receipt and spending with family health.
    PLoS One. 2025;20:e0328389.
    PubMed         Abstract available

  33. FRANCO VF, Zaccara TA, Ferreira OS, da Costa RA, et al
    Unveiling the hidden burden of COVID-19 in Brazil's obstetric population with severe acute respiratory syndrome: A machine learning model.
    PLoS One. 2025;20:e0330375.
    PubMed         Abstract available

  34. RAFEI R, Osman M, Barake BA, Mallat H, et al
    Shifting respiratory pathogens: Post-COVID-19 trends in community-acquired infections in underserved communities.
    PLoS One. 2025;20:e0329481.
    PubMed         Abstract available

  35. ZHANG J, Hou C, Chen W, Hu Y, et al
    Comorbidity patterns associated with severe COVID-19 outcomes: A cohort study based on the UK Biobank.
    PLoS One. 2025;20:e0329701.
    PubMed         Abstract available

  36. JIN H, Ding X, Li Z, Cao J, et al
    Community volunteer participation and its determinants during respiratory infectious disease outbreaks in China: A cross-sectional study across multiple provinces.
    PLoS One. 2025;20:e0330838.
    PubMed         Abstract available

  37. CAMPBELL JT, Viegas de Moraes Leme LF, Gesselman AN
    Infidelity among parents in committed relationships during the COVID-19 pandemic.
    PLoS One. 2025;20:e0329015.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  38. YIN S, Zhang C, Teitelbaum CS, Si Y, et al
    Landscape changes elevate the risk of avian influenza virus diversification and emergence in the East Asian-Australasian Flyway.
    Proc Natl Acad Sci U S A. 2025;122:e2503427122.
    PubMed         Abstract available

  39. WANG S, Sun H, Wang Y, Wang Z, et al
    Broad neutralizing antibody response of a monomeric spike-based SARS-CoV-2 bivalent vaccine against diverse variants.
    Proc Natl Acad Sci U S A. 2025;122:e2503254122.
    PubMed         Abstract available


    Vaccine

  40. BREWER NT, Rockwell EM, Tomar A, Fisher EB, et al
    Covid-19 vaccine incentives' effectiveness and differential impact on high-risk groups: A prospective cohort study.
    Vaccine. 2025;61:127302.
    PubMed         Abstract available

  41. ANASTASSOPOULOU C, Panagiotopoulos AP, Ferous S, Poland GA, et al
    RSV vaccines and Guillain-Barre syndrome: Insights into an emerging concern.
    Vaccine. 2025;61:127338.
    PubMed         Abstract available

  42. MARQUEZ AC, Beitari S, Valadbeigy T, Sbihi H, et al
    COVID-19 serological survey utilizing antenatal serum samples in British Columbia.
    Vaccine. 2025;61:127310.
    PubMed         Abstract available

  43. ROSENMAN KD, Wang L
    Variation of COVID-19 vaccination percentage by industry and occupation in Michigan.
    Vaccine. 2025;61:127349.
    PubMed         Abstract available

  44. ALSHURMAN BA, Majowicz SE, Grindrod K, Goh J, et al
    Psychometric validation of the COVID-19 vaccine hesitancy scale for primary and booster doses among university students: A cross-sectional study.
    Vaccine. 2025;61:127368.
    PubMed         Abstract available

  45. OMAR M, Shibli H, Edelstein M
    Comparative impact of the COVID-19 pandemic on parental behaviour towards childhood vaccination in Israel and the United Kingdom: A self-controlled matched cross-sectional study.
    Vaccine. 2025;61:127385.
    PubMed         Abstract available

  46. MARIJAM A, Marijic P, Puggina A, Cailloux O, et al
    Older adults' and physicians' preferences for respiratory syncytial virus vaccination in Germany and Italy: A discrete choice experiment.
    Vaccine. 2025;61:127390.
    PubMed         Abstract available

  47. ROSENTHAL S, Chuah ASF, Kim HK, Ho SS, et al
    Direct and indirect experiences, risk perceptions, and vaccine booster intention: A mediation study in Singapore using secondary risk theory.
    Vaccine. 2025;61:127435.
    PubMed         Abstract available

  48. AL-KASSAB-CORDOVA A, Mezones-Holguin E, Kaufman JS
    Education as a mediator of ethnic disparities in adult COVID-19 vaccination in Peru.
    Vaccine. 2025;61:127436.
    PubMed         Abstract available

  49. MACKE CA, Carreon SA, Desai KR, Minard CG, et al
    COVID-19 vaccine uptake and attitudes in emerging adults with type 1 diabetes.
    Vaccine. 2025 Apr 6:127083. doi: 10.1016/j.vaccine.2025.127083.
    PubMed         Abstract available

  50. LLOYD PC, Acharya G, Zhao H, Chen B, et al
    Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Commercially-insured individuals aged 6 months through 64 years: Self-controlled case series analyses.
    Vaccine. 2025;63:127614.
    PubMed         Abstract available


    Virology

  51. BADR C, Arbi M, Souiai O, Larbi I, et al
    Tracing the 2021 equine influenza Outbreak: First characterization and phylogeographic analysis of H3N8 Florida clade 1 virus in Tunisia.
    Virology. 2025;611:110655.
    PubMed         Abstract available


    Virus Res

  52. MARTINEZ ES, Fuchs S, Szurmant H, Chen X, et al
    COVID-19 mRNA vaccine immune response to the addition of osteopathic manipulative treatment with lymphatic pumps: a randomized controlled trial.
    Virus Res. 2025 Jul 14:199607. doi: 10.1016/j.virusres.2025.199607.
    PubMed         Abstract available

  53. WU J, Qian X, Bai S, Wu L, et al
    Lesser-known non-apoptotic programmed cell death in viral infections.
    Virus Res. 2025;359:199612.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »